OncoMatch

OncoMatch/Clinical Trials/NCT04641247

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Is NCT04641247 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Niraparib for ovarian neoplasms.

Phase 2RecruitingGlaxoSmithKlineNCT04641247Data as of Jun 2026Location: International · 8 countries

Treatment: NiraparibThis is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

Niraparib

Cancer type

Ovarian Cancer

Breast Carcinoma

Prior therapy

Must have received: PARP inhibitor (niraparib) — parent GlaxoSmithKline/TESARO-sponsored study

currently receiving treatment with niraparib (as monotherapy or in combination) in a GlaxoSmithKline/TESARO-sponsored study that has fulfilled the requirements for the primary objective

Cannot have received: PARP inhibitor (niraparib)

has been permanently discontinued from niraparib treatment in the parent study for any reason

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • GSK Investigational Site · Tucson, Arizona
  • GSK Investigational Site · Encinitas, California
  • GSK Investigational Site · Los Angeles, California
  • GSK Investigational Site · Whittier, California
  • GSK Investigational Site · Jacksonville, Florida

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT04641247 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior PARP inhibitor disqualifies patients from enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify